CytOSorb TreatMent Of Critically Ill PatientS Registry

Launched by CYTOSORBENTS, INC · Nov 23, 2021

Keywords

ClinConnect Summary

The CytOSorb TreatMent Of Critically Ill PatientS Registry is a study designed to gather information about the use of a device called CytoSorb in critically ill patients. The device is intended to help filter harmful substances from the blood in patients suffering from serious conditions like septic shock, acute respiratory distress syndrome, and complications from surgeries or infections. The goal of this registry is to create a reliable database that can help healthcare providers monitor and improve the quality of care that patients receive when using this device.

To participate in this study, patients need to be scheduled to use the CytoSorb device and must give their consent to take part. The study is open to all patients, regardless of age or gender. However, those using the device solely for certain types of blood treatments or during specific surgeries may not be eligible. Participants can expect to contribute to valuable research that may enhance treatment options for critically ill patients, helping doctors understand better how this device works in real-life situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Planned OR actual CytoSorb® 300 mL device utilization
• • 2. Informed consent for prospective registry participation
• Exclusion Criteria:
• • 1. Use of the CytoSorb® 300 mL device for antithrombotic removal only
• • 2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
• • 3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.